Abstract Details

Title In-Stent Occlusion and Re-Stenosis among Patients Taking Interferon beta-1a: A Report from FDA Adverse Event Reporting System

Topic Interventional Neurology

Presentation(s) P07 - (-)

Poster/Presentation
Number 271

Objective

Background BACKGROUND: Interferon beta -1a is used in multiple sclerosis as an immune modulator that is being used to reduce relapses of relapsing-remitting multiple sclerosis in approximately 178,000 in the United States. The medication has an FDA warning of potentially causing chest pain, heart failure or cardiomyopathy through an unknown mechanism.

Design/Methods DESIGN/METHODS: The FDA Adverse Event Reporting System (FDA-AERS) tracks all potential adverse events for all FDA approved medications. We queried the FDA-AERS database for all reports including "stent" from 2004 to 2009 for patients taking interferon beta-1a. We included stents to the coronary arteries, and reports of in-stent restenosis or occlusion.

Results RESULTS: Overall there were 52 adverse event reports of patients receiving coronary stents with concurrent interferon beta -1a. There were 9 (18%) reports of patients who had in stent restenosis or occlusion that required treatment. Of the patients who had stent occlusion or restenosis, the average age was 60 years and 5 were women. The average duration of Interferon beta-1a therapy was 3.5 years prior to the event. One additional patient died from acute myocardial infarction two weeks after receiving a stent but there was no information on whether the stent occluded.

Conclusions CONCLUSIONS: The occurrence of in-stent restenosis and occlusion in patients on Interferon beta-1a warrants further investigation and possible discontinuation of medication prior to stent placement.

Authors/Disclosures
Kenneth Shea, MD (Saint Cloud Hospital) PRESENTER	No disclosure on file
	No disclosure on file
Hamza I. Maqsood, MD (Dept of Neurology)	Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.
Seward B. Rutkove, MD, FAAN	Dr. Rutkove has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Myolex, Inc. Dr. Rutkove has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neuorlogy . The institution of Dr. Rutkove has received research support from NIH. The institution of Dr. Rutkove has received research support from NASA. The institution of Dr. Rutkove has received research support from Blavatnik Family Foundation. Dr. Rutkove has received intellectual property interests from a discovery or technology relating to health care. Dr. Rutkove has received intellectual property interests from a discovery or technology relating to health care. Dr. Rutkove has received publishing royalties from a publication relating to health care. Dr. Rutkove has received publishing royalties from a publication relating to health care. Dr. Rutkove has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with NIH.

��ɫ��

��ɫ��